🇺🇸 FDA
Pipeline program

mPEG-r-crisantaspase

AZPO2-CLT-001

Phase 1 mab completed

Quick answer

mPEG-r-crisantaspase for Hematologic Malignancies is a Phase 1 program (mab) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Hematologic Malignancies
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials